Atlas Trials

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Clinical trial NCT03677557 · UNKNOWN

Trial details

NCT number
NCT03677557
Sponsor
Ottawa Hospital Research Institute
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Primary Immunodeficiency DiseaseSecondary Immunodeficiency
Start date
2018-09-19
Primary completion
2021-08-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.